Physician profile
Edward A Capone
NPI 1396749131
$1,067.17
in general payments reported to CMS, 2019-2025
20 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $72.56 · 2021: $190 · 2022: $220 · 2023: $197 · 2024: $80.53 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $248.39 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $178.70 | 2020-2023 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $114.45 | 2019 | |
| Eisai INC. | $95.25 | 2021 | |
| Pfizer INC. | $63.54 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $42.40 | 2022 | |
| Abbvie INC. | $38.59 | 2021 | |
| Biocomposites INC | $35.86 | 2025 | Stimulan |
| Lifenet Health | $33.55 | 2024 | Theragenesis Wound Matrix |
| Phadia US INC. | $28.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.21 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.21 | 2023 | Rexulti |
| Dexcom, INC. | $24.47 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $24.02 | 2020 | |
| Amgen INC. | $19.83 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $14.66 | 2020 | |
| Allergan, INC. | $14.66 | 2021 | |
| Lifescan, INC. | $14.11 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Capone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.